{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.68","value":"5.8"},{"groupId":"OG001","spread":"3.708","value":"6.09"}]}],"title":"Week 6 (n= 64, 94)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.43","value":"6.59"},{"groupId":"OG001","spread":"3.504","value":"6.86"}]}],"title":"Week 24 (n= 64, 89)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.11","value":"7.28"},{"groupId":"OG001","spread":"3.214","value":"7.07"}]}],"title":"Week 48 (n= 23, 86)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.19","value":"6.08"},{"groupId":"OG001","spread":"3.66","value":"7.25"}]}],"title":"Week 72 (n= 4, 92)"},{"categories":[{"measurements":[{"comment":"No participant was evaluable, so value was not available.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"3.697","value":"7.09"}]}],"title":"Week 96 (n= 0, 83)"},{"categories":[{"measurements":[{"comment":"No participant was evaluable, so value was not available.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"3.35","value":"7.28"}]}],"title":"Week 144 (n= 0, 69)"},{"categories":[{"measurements":[{"comment":"No participant was evaluable, so value was not available.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"2.507","value":"5.85"}]}],"title":"Week 240 (n= 0, 13)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"description":"The participants were assessed for everolimus trough concentration (Cmin) at 24 hours time point after previous dose administration, at a steady state following 5 days of consistent dosing, if the participant did not vomit within 4 hours of previous dose. Tandem liquid chromatography-mass spectrometry method was used for evaluation. Cmin values were categorized as \\<5 ng/mL, 5-10 ng/mL, and \\>10 ng/mL, concentrations below the lower limit of quantification were entered as 0 ng/mL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received oral dose of everolimus 4.5 mg/m\\^2 daily as an initial starting dose to attain the whole blood trough concentrations in range of 5-15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations.","id":"OG000","title":"Everolimus (Core Period)"},{"description":"Participants received oral dose of everolimus 4.5 mg/m\\^2 daily as an initial starting dose to attain blood trough concentrations in range of 5-15 ng/mL.","id":"OG001","title":"Everolimus (Extension Period)"}],"paramType":"MEAN","populationDescription":"The analysis was performed in the Safety Set population. The 'n' signifies those participants evaluable for this measure at specified time points for each group, respectively.","reportingStatus":"POSTED","timeFrame":"24 hours post dose on Week 6, Week 24, Week 48, Week 72, Week 96, Week 144, and Week 240","title":"Everolimus Trough Concentrations (Cmin) at 24 Hours After Last Dose","type":"SECONDARY","unitOfMeasure":"ng/mL"}